Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including brain inhibitory neurons; strongest in prostatic glandular cells | 0.75 |
| chemistry Open Targets | reachable by antibody: voclosporin | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 3 Parkinson's papers of 197 | 0.82 |
| pathways Reactome | 5 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 11403
Sealed predictions
- PPP3CA in dopamine neurons, braak+0.06 (p 0.886) → -0.42 (p 0.258)receipt 11414
Swarm cases
receipt 11414: PPP3CA in dopamine neurons, braak
- power
- full sample -0.06 (p 0.820, n 18), 95% CI -0.51 to +0.42. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.01 (p 0.962, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.06 (p 0.807, n 18). could be the mix.
- skeptic
- leave-one-out range -0.21 to +0.07, sign flips 4; without severely affected donors -0.06 (p 0.820, n 18). fragile.
- cell type
- strongest in oligodendrocytes: -0.59 (p 0.0096, n 18) vs -0.06 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for PPP3CA in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up PPP3CA · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.07 p 0.790 (needs p < 1.9e-4)
Receipts
loading the receipts